DR Leanne Robinson

DR Leanne Robinson

Positions

Overview

OverviewText1

  • www.wehi.edu.au/people/leanne-robinson

    My research aims to better understand, diagnose, treat and prevent mosquito-borne parasitic diseases, particularly malaria and filariasis.

    I am based at the Papua New Guinea Institute of Medical Research (PNGIMR) in Madang, where I head the Vector Borne Diseases Unit. My laboratory’s research is highly collaborative and we conduct clinical, field and laboratory-based studies.

    Our goal is to inform the development and implementation of effective, evidence-based public health programs that will ultimately lead to the elimination of malaria and filariasis. I also aim to use our research program to develop the capacity of young researchers in Papua New Guinea (PNG).   

Publications

Selected publications

Awards

Education and training

  • PhD, University of Melbourne

Supervision

Available for supervision

  • Y

Supervision Statement

  • Research interest

    Areas of particular interest include:

    - Measuring the impact of intensified malaria control on the epidemiology and transmission of malaria in PNG.
    - Revealing the burden of Plasmodium vivax infection and illness attributable to relapses from hypnozoites.
    - Understanding how clinical immunity to malaria is acquired by infants, children and pregnant women and identifying immunological correlates of protection.
    - Defining how immunological memory to malaria develops, and the impact of pre-natal exposure to malaria on immune responses and all-cause morbidity during infancy.
    - Discovering serological markers of recent malaria exposure for development as potential tools in pre-elimination settings.
    - Determining the infectivity of symptomatic and asymptomatic P. falciparum and P. vivax infections to mosquitoes.
    - Conducting intervention trials of anti-malarial drug combinations and intermittent preventative therapy during infancy and pregnancy.
    - Developing drug regimes for malaria and filariasis mass drug administration campaigns.
    - Testing in vitro drug sensitivity and drug resistance.
    - Investigating effective strategies for population-level screening of glucose-6-phosphate dehydrogenase (G6PD) deficiency for use in future mass treatment programs that may utilise primaquine or tafenoquine.